Key result
Fondaparinux reduced the risk of all-cause mortality at 90 to 180 days compared to UFH or LMWH in patients with acute coronary syndromes (RR 0.89; 95% CI 0.81 to 0.97).
Why the study?
Do factor Xa inhibitors improve clinical outcomes and safety in patients with acute coronary syndromes compared to UFH or LMWH?
Systematic Review (n=27,976)
Do factor Xa inhibitors improve clinical outcomes and safety in patients with acute coronary syndromes compared to UFH or LMWH?
Relative Risk: 0.89 (95% CI 0.81–0.97)
In patients with acute coronary syndromes, fondaparinux reduces all-cause mortality and bleeding risk compared to enoxaparin.
No takes yet. Share an insight, caveat, or question.
Supports fondaparinux preference in ACS; confirms mortality benefit over UFH/LMWH in pooled RCTs.
Brito et al. (2011) conducted a systematic review in acute coronary syndromes (n=27,976). Factor Xa inhibitors (Fondaparinux) vs. UFH or LMWH (enoxaparin) was evaluated on all-cause mortality at 90 to 180 days (RR 0.89, 95% CI 0.81 to 0.97). Fondaparinux reduced the risk of all-cause mortality at 90 to 180 days compared to UFH or LMWH in patients with acute coronary syndromes (RR 0.89; 95% CI 0.81 to 0.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: